The German Healthcare Sector



Nils Roeher U.S. Commercial Service Germany November 2005

INTERNATIONAL COPYRIGHT, U.S. DEPARTMENT OF COMMERCE AND DEPARTMENT OF STATE. ALL RIGHTS 2005, RESERVED OUTSIDE OF THE UNITED STATES.

SUMMARY

2004 was the first year after the German healthcare reform, the so-called "Statutory Health Insurance (SHI) Modernization Act." The reform led to uncertainty among both doctors and patients. It also had a substantial impact on the German medical industry and health care infrastructure. A rising number of Germans would like to take advantage of diagnostic therapeutic treatments. This is obstructed by the strained financial situation of the SHI. Thus, the German health ministry is facing the challenge of establishing what kind of medical services will continue to be covered by the SHI. "Health premiums" and "citizen insurance" are the two models currently discussed by German politicians.

In the long term, only a fundamental reorganization to a market-driven healthcare system with increased competition will guarantee affordable, high-quality healthcare.

THE GERMAN HEALTH CARE SYSTEM

The German health care system is facing tremendous challenges. As life expectancy rises, elderly people are requiring longer medical care and the number of elderly committed to hospitals or nursing homes because of geriatric disorders or chronic diseases is growing steadily. The changes in population size and structure in Germany over the past years have had a negative impact on the financing of the German social security system and herald more dramatic changes for the future.

In Germany, the term "health care system" encompasses all institutions and individuals who contribute to, support, and restore the health of the population. Federal and state governments are responsible for the maintenance of the public health care system; all insured persons receive health care benefits; and suppliers of such services are remunerated directly by the insurance funds.

Nearly 90% of the German population, or 72 million people, are insured in the statutory health insurance (SHI), the public sickness funds. In 2003, SHI's total expenditures amounted to EUR 144.5 billion.

MARKET OVERVIEW

Healthcare Reform

In 2004, the SHI Modernization Act (GKV-Modernisierungsgesetz – GMG) came into effect and temporarily relieved statutory health insurance funds of some of their financial. In the third quarter of 2004, sickness funds reported a surplus of some EUR 2.6 billion. The federal government's goal of decreasing SHI contribution rates to an average 13.6% by way of this reform failed. The surplus gained by the sickness funds was mostly spent on the reduction of their accumulated financial deficits, which amounted to EUR 8 billion in total. The positive development of the SHI funds' financial status was a result of increased co-payments of patients, e.g., the practice fee, and secondly, of restrictions in the provision of services and expenditures on pharmaceuticals. Experitures on drugs decreased by EUR 2.4 billion in 2004 compared

to 2003, owing to the exclusion of non-prescription medications from reimbursement as well as to the manufacturer's rebate ("Herstellerrabatte").

Structural Measures within the SHI Modernization Act (GMG)

Medical care experts expect that the newly established Institute for Quality and Cost-Effectiveness in the Health Care System (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen – IQWiG) will substantially influence the design of future health care. One of the institute's tasks is the evaluation of medical diagnosis and treatment methods. The most significant changes for the quality of healthcare begin to emerge with the new provisions for integrated care, intended to break through the strict separation of healthcare sectors. By allocating 1% of physicians' fees or hospital budgets, respectively, to integrated care, the SHI Modernization Act provides an initial financing pool of EUR 680 million annually for the advancement of this tool. By ember 2004, 239 integrated care contracts had been registered and 89 medical treatment centers had been approved.

2004: Mandatory DRG (Diagnosis Related Groups) Introduction

2004 was the last budget-neutral year for German acute care hospitals. The German flat-rate reimbursement catalogue (G-DRGs) encouraged hospitals to restructure. By the end of 2004, 86% of the 1,836 hospitals affected had changed to the DRG system. The change in hospital reimbursement also alters the structures of the German hospital landscape. Part of the inadequately funded municipal facilities were privatized by their operating institutions or sold to private operators. This did not even stop at maximum care providers such as university hospitals. The financial pressure on hospitals has been passed on to the medical technology companies. Procurement of medical devices has been standardized and streamlined by purchasing networks. The new catalogue is more complex than the previous one. It comprises 878 DRGs and 71 supplementary payments. Supplementary payments also include "emerging" medical technologies, which were not before.

Impacts on Innovation

If hospital-individual base rates are adjusted to a uniform national base rate, hospitals with a high base rate run the risk of losing out. This would particularly affect maximum care providers such as university hospitals, which for the most part use innovative, high-value medical technologies. An expert report recommended a differentiation of hospitals according to their levels of care and an extension of the convergence phase until the base rates are adequately adjusted. Parts of this recommendation, such as the extension of the convergence phase, have been included in the DRG amendment law.

Impacts of the SHI Modernization Act , in effect as of January 2004, had a particularly dramatic impact on the medical technical aids industry. In the first three quarters of 2004, this segment saw 13.7% decrease in expenditures. The share of technical aids in the SHI's total expenditures within this period of time amounted to only 3.18% – compared to 3.58% in the previous year. Meanwhile, co-payments, additional payments, nationwide reference prices, changes in reimbursement and the resulting difficulties have left their mark on patients and care providers. Some of the most significant problems in implementing the law are a result of vague phrasing in and differing interpretations of the law. This has led to substantial uncertainties among all participants in the medical technical aids market.

v-Price Policy raises Question of Quality

The GMG caused extreme price cuts in the technical aids sector. Sickness funds, for instance, revoked existing contracts. Furthermore, an increasing number of care providers had to file for insolvency. Manufacturers were not spared the GMG's repercussions either. Due to the increased pressure on sales and prices, they had to accept sales decreases of up to 40% in 2004. This low-price policy harbors the risk of causing a decline in quality in the medium term. It is feared that care providers will not

be able to maintain their service in the present quality. Manufacturers are increasingly forced to relocate their production facilities to low- wage countries and/or reduce the high quality of their products to a sickness fund standard quality.

Federal Reference Prices

On 1 January 2005, federal reference prices for various product groups of the medical technical aids register ("Hilfsmittelverzeichnis-HMV") came into effect; including: arch supports; technical aids for compression therapy; visual and hearing aids; absorbing incontinence aids. It is planned to stipulate reference prices for 70 % of all medical technical aids. In total, 253 reference prices were set. 35 % of the prices were increased; 64 % remained at the same level.

Increased Appreciation of Homecare

German legislative bodies and statutory health insurance funds are still not taking the growing significance of homecare into account. Homecare is characterized by the qualified and professional provision of advice and support on the use of technical aids, often in combination with drugs, dressing materials or medical devices that are sold exclusively by pharmacies. Homecare services are almost exclusively financed via product compensation, and the reimbursement of technical aids in particular. Decreasing reference prices and a price determination considering nothing but the cost of the product put this sector of healthcare, which represents a crucial link between the pure supply of products and the treatment and care of patients in their own home environment, increasingly at risk. The rising tendency towards flat-rate reimbursement also endangers customized patient care.


Pressure on Prices and Administration Costs


Small, local homecare companies particularly suffer from the severe price competition among care providers. They are faced with increasing administrative costs arising from co-payments; sickness fund individual reimbursement procedures; individual contracts rather than general agreements; participation in tenders. It is as yet unclear how the introduction of an electronic prescription planned for 2006, as part of an electronic health insurance card, would affect the homecare market. The implementation of the necessary technology will unquestionably result in considerable extra costs for care providers.

New Models of Care: Integrated Care and Medical Healthcare Centers

With the GMG, the development of new healthcare structures gained additional momentum. Legal requirements for the conclusion of integrated care agreements were deregulated and allow for individual agreements between sickness funds and care providers. Thus, homecare companies can now become contracting parties, too. Manufacturers can indirectly get involved in integrated care in the form of management companies. The start-up financing provided for by the GMG triggered a downright contracting race among sickness funds. More than 200 contracts were concluded in 2004. They differ significantly in terms of the character and extent of care agreed upon, the following healthcare areas predominant: Endoprosthetics; cardiovascular surgery; interventional cardiology /care for the chronically ill; coronary heart diseases; hospitalbased outpatient care according to § 115b of the German Social Code, Book Five, and breast cancer diagnostics and therapy, mainly reimbursed via complex flat rates. In contrast to integrated care agreements, implementation of medical healthcare centers has started somewhat sluggishly. The law does not provide for the involvement of industry or trade. Nevertheless, it is apparent that many homecare companies and providers of health supplies perceive cooperation with medical healthcare centers as an important strategic market positioning tool.

Statistical Data






In 2003 (the year for which most recent official figures were provided by the Federal Statistical Office), expenditures in the health care sector amounted to EUR 239 billion compared to EUR 163 billion spent in 1992.

Gross domestic product (GDP) and health care expenditures - Germany

Year	GDP in EUR billion	Healthcare expenditures in EUR billion	Health care expenditures as % of GDP
1992	1,615	163	10.1
1993	1,648	168	10.2
1994	1,733	180	10.4
1995	1,796	194	10.8
1996	1,829	203	11.1
1997	1,871	204	10.9
1998	1,930	208	10.8
1999	1,984	214	10.8
2000	2,026	219	10.8
2001	2,065	227	11.0
2002	2,110	234	11.1
2003	2,130	239	11.2



The Statutory Health Insurance (SHI) accounts for approximately half of these annual expenditures. In 2003, for example, the SHI paid EUR 145 billion of total health care expenditures of EUR 239 billion.

Gross Domestic Product (GDP) and Statutory Health Insurance Expenditures (SHI)

Year	GDP in EUR billion	SHI Expenditures in EUR billion	SHI share in expenditures as % of GDP
1970	345	13	3.8
1980	754	46	6.1
1990	1,231	73	5.9
1995	1,769	124	7.0
1996	1,829	128	7.0
1997	1,871	125	6.7
1998	1,930	127	6.6
1999	1,984	131	6.6
2000	2,026	134	6.6
2001	2,065	139	6.7
2002	2,110	143	6.8
2003	2,130	145	6.8

Health care expenditures (2002) by large institutions:

EUR 9.6 billion (4.1%) - public and private sector employers; EUR 18.4 billion (7.9%) - public administrations;

EUR 4.3 billion (1.8%) - the three German pension fund providers;

EUR 19.7 billion (8.4%) - private health insurance providers;

EUR 16.4 billion (7.0%) - nursing-care insurance ("Pflegeversicherung")

EUR 4.0 billion (1.7%) - statutory accident insurance;

EUR 28.5 billion (12.2%) – other public and private non-profit organizations

SHI expenditures 2003: in EUR billion

Sector	2002	2003	Growth Rate	Share of total SHI expenditures
hospital	46.152	46.845	1.5%	32.4%
sickness benefits ("Krankengeld")	7.56	6.968	-7.8%	4.8%
administration	8.019	8.038	0.2%	5.6%
others	14.062	13.165	-6.4%	9.1%
remedies + technical aids	9.304	9.257	-0.5%	6.4%
dentists / protheses	11.492	11.786	2.6%	8.2%
medication	23.44	24.196	3.2%	16.7%
medical therapy Total	22.309 142.338	24.276 144.531	8.8% 1.5%	16.8%

Health expenditures by type of benefit in EUR billion

Type of benefit	2001	2002	2003
Total benefits	227.788	234.967	239.703
Prevention/ Health Protection	10.329	10.728	11.096
Medical benefits	59.783	60.913	62.278
Custodial/therapeutic benefits	51.902	53.934	54.746
Balance consequences due to illness	4.467	4.668	4.823
Accommodation/catering	14.664	14.891	14.953
Commodities	60.479	62.370	64.142
Pharmaceuticals	35.004	36.591	37.547
Additives	12.076	12.308	12.746
Other medical equipment	7.385	7.596	7.669
Transportation	3.616	3.828	3.968
Administration	11.928	12.645	13.155
Research/Training/Investment	10.619	10.988	10.542

	Hospitals		patient fluctuation					
	a total of Beds in use			Charging	average			
year		number of cases	and Occupancy days	retention period	beds efficiency			
	quantity		in 1,000		in days	in %		
1991	2,411	665,565	14,577	204,204	14.0	84.1		
1992	2,381	646,995	14,975	198,769	13.2	83.9		
1993	2,354	628,658	15,191	190,741	12.5	83.1		
1994	2,337	618,176	15,498	186,049	11.9	82.5		
1995	2,325	609,123	15,931	182,627	11.4	82.1		
1996	2,269	593,743	16,165	175,247	10.8	80.6		
1997	2,258	580,425	16,429	171,837	10.4	81.1		
1998	2,263	571,629	16,847	171,802	10.1	82.3		
1999	2,252	565,268	17,093	169,696	9.9	82.2		
2000	2,242	559,651	17,263	167,789	9.7	81.9		
2001	2,240	552,680	17,325	163,536	9.4	81.1		
2002	2,221	547,284	17,432	159,904	9.2	80.1		
2003	2,197	541,901	17,296	153,518	8.9	77.6		

Prevention, Beds and Patient Fluctuation Arrangement of Prevention and Rehabilitation 1991 - 2003							
	Arrangement of Prevention or Rehabilitation		Patient Fluctuation				
year		Beds in use	number of cases	care days	average		
	a total of				retention period	beds efficiency	
	Quantity		in 1,000		in days	in %	
1991	1,181	144,172	1,473	45,729	31.0	86.9	
	1,209	149,910	1,575	48,833	31.0	89.0	
1993	1,245	155,631	1,632	50,469	30.9	88.8	
1994	1,329	172,675	1,765	55,069	31.2	87.4	
1995	1,373	181,633	1,896	58,820	31.0	88.7	
1996	1,404	189,888	1,917	57,839	30.2	83.2	
1997	1,387	188,869	1,575	42,972	27.3	62.3	
1998	1,395	190,967	1,746	46,107	26.4	66.1	
1999	1,398	189,597	1,915	49,874	26.0	72.1	
2000	1,393	189,822	2,046	52,852	25.8	76.1	
2001	1,388	189,253	2,097	53,514	25.5	77.5	
2002	1,343	184,635	2,041	52,107	25.5	77.3	
2003	1,316	179,789	1,900	49,204	25.9	75.0	

Tariffs, Import regulations

Official trade barriers, such as quotas, do not exist. The importation of dental products into Germany is duty-free. A 16% import-turnover Tax ("Einfuhrumsatzsteuer") must be paid at the port of entry, and is, in later distribution stages, passed on to the ultimate end-user in the form of the value-added tax (VAT or "Mehrwertsteuer" - MWSt). For customs clearance, a product label is required, which describes the use, origin and value of the product.

Trade restrictions and safety regulations

Although no trade restrictions or other non-tariff barriers (such as quotas) apply to the sale of imported health care service products or parts/accessories for healthcare services on the German market, all equipment used in healthcare servicing must comply with German (and/or European) safety regulations and technical standards.

All electrical equipment in Germany must be suitable for use with 220 Volt, 50 cycle electrical current. Since January 1, 1996, CE approval is mandatory for all products sold on the European market. By marking their products with the CE approval symbol, manufacturers guarantee that their products correspond to the EU guidelines for electrical and electronic devices.

Furthermore, electrical equipment should have VDE or TUEV-approval. A "UL" approval is not a substitute but is helpful in obtaining "GS/VDE," or "GS/TUEV" approval in Germany. "GS" stands for "geprüfte Sicherheit" (safety-tested). Although "GS" and the "VDE" (or "GS" and TUEV") marks are not required by law, they are highly recommended

for marketing electrical goods in Germany. These labels denote high product safety. German consumers look for these labels as Americans do for the "UL" mark.

The U.S. product safety testing institute Underwriters Laboratories (UL), the VDE Testing and Certification Institute, the TUEV Product Service, and the IMQ (Product and Quality System Certification in Italy) have formed a strategic alliance in the field of electromagnetic compatibility (EMC). The result of this co-operation has been an EMC test mark recognized worldwide. For manufacturers of electrical and electronic products, this co-operation has led to a considerable simplification of EMC testing. Through a single test carried out by one of these four partners, a product can now be awarded an international EMC mark, which replaces the national test marks in the major world markets of Europe, the United States, Japan and Australia (more information on http://www.intlemcmark.com).

Contact information for the two testing institutes VDE and TUEV:

VDE - Verband Deutscher Elektrotechniker e.V.

Prüf- und Zertifizierungsinstitut (VDE Testing Division)

Merianstraße 28 DE-63069 Offenbach Tel 1: 49 69 8306-0 Tel 2: 49 69 8306-600 Fax: 49 69 8306-555

Internet: www.vde.de/vde_pi

E-Mail: vde-institut@vde.com

VDE Authorized Offices, VDA Expatriates, VDE Liaison Offices and VDE Liaison Addresses in the United States

Heinz Rosen <u>Dallas (Lewisville)</u> <u>Melville</u>

VDE Authorized Office Frank Richter Underwriters Laboratories Inc. 9 Cedar Valley Lane 355 E. Vista Ridge Rd., Apt. 3921 ICS Dept. 1285 Walt

Whitman Road

Huntington, NY 11743 Lewisville, TX 75067 Melville, Long Island
Tel: 516-730-654 Tel: 214-488-4496 NY 11747-3081
Fax: 516-4246-248 Fax: 214-488-4966 Tel: 516-271-6200
Email:muhandas@aol.com Email: frank.richter@vde.com Fax: 516-439-

6071

Entela Inc. Underwriters Laboratories Inc. <u>Batesville</u>

3033 Madison Ave. International Compliance Service Hans-Werner Zeller Grand Rapids, MI 49548 Department ICS 26022 Arbor Lake Drive Tel: 616-247-0515 333 Pfingsten Road Batesville, Indiana

47006

Fax: 616-574-9752 Northbrook, IL 60062-2096 Tel: 812-933-1002 E-mail: thubbard@entela.com Tel: 847-272-8800 Fax: 812-933-0345

Fax: 847-272-8129 E-mail: hans-

werner.zeller@vde.com

TUEV Rheinland GmbH	TUEV Süddeutschland Holdi	ng AG	TUEV NORD
(TUEV Rhineland)	(TUEV South Germany)	(TUE	V North Germany)

Am Grauen Stein Westendstraße 199 Am TÜV 1

D-51105 Köln D-80686 München D-30519 Hannover
Tel: 49-221-806 0 Tel: 49-89-5791-0 Tel: 49-511-986-0
Fax: 49-221-806-3406 Fax: 49-89-5791-1551 Fax: 49-511-986-1237
E-mail info@tuev-rheinland.de E-mail: info@tuev-

<u>sued.de</u> E-mail: <u>info@tuev-nord.de</u>

Internet <u>www.tuev-rheinland.de</u> Internet: <u>www.tuev.sued.de</u>

Internet: info@tuev-nord.de

TUEV in the United States

TUV Rheinland of North America Inc. 12 Commerce Road

Newtown, CT 06470 USA

Tel.: 203-426-0888 Fax: 203-426-4009 E-mail: <u>info@tuv.com</u>

Internet: http://www.us.tuv.com (further U.S. offices of the TUEV can be found on this

Website)

TRADE PROMOTION OPPORTUNITIES

FUSE

FUSE – Featuring U.S. Exporters: U.S. manufacturers looking for sales leads or potential sales representatives in Germany can list their products and services on the German-language version of the U.S. Commercial Service website, www.buyusa.gov/germany, which targets an audience of German importers, distributors and commercial buyers. It allows a search via keyword.

Commercial News USA

Commercial News USA is the official United States Department of Commerce showcase for American-made products and services. The catalog-style magazine is designed to help American companies promote products and services to buyers in more than 145 countries. Each issue reaches an estimated 400,000 readers worldwide. For more information, please visit: www.thinkglobal.us

Major Trade Shows

In Germany trade fairs play a major role in product marketing. U.S. companies wishing to penetrate the German market often make their first approach at major trade fairs. For U.S. manufacturers and exporters wishing to sell in Germany (and in Europe) it is important to exhibit at one of Germany's major international fairs. Exhibiting at fairs can bring direct sales, but, more significantly, it can be one of the least expensive ways to test the market's receptivity. Further the strength and scope of the competition can be assessed and contacts with others "in the trade" can be established. From these contacts, U.S. companies can gather a great deal of valuable information about

marketing in Germany and Europe. The most suitable trade shows in the healthcare sector are:

MEDICA - World Forum for Medicine - International Trade Fair and Congress. With ComPaMED International Trade Fair for Components, Parts and Raw Materials for Medical Manufacturers.

Organizer:

Messe Düsseldorf GmbH

Messeplatz · 40474 Düsseldorf

Tel: +49-211-4560-01 · Fax: +49-211-4560-668

http://www.messe-duesseldorf.de E-mail: info@messe-duesseldorf.de

Project team:

MEDICA Tel: +49-211-4560-529 · Fax: +49-211-4560-87529 E-mail: info@messe-duesseldorf.de · http://www.medica.de

In the United States:

Messe Düsseldorf North America

150 North Michigan Avenue, Suite 2920 Chicago, IL 60601

Tel: +1 (312) 781 51 80 · Fax:+1 (312) 781 51 88

E-Mail: info@mdna.com

Website: http://www.mdna.com

REHACARE INTERNATIONAL - International Trade Fair for Those with Special Needs and Those Requiring Care

Organizer:

Messe Düsseldorf GmbH

Messeplatz · 40474 Düsseldorf

Tel: +49-211-4560-01 · Fax: +49-211-4560-668

http://www.messe-duesseldorf.de E-mail: info@messe-duesseldorf.de

Project team:

Tel: +49-211-4560-900 · Fax: +49-211-4560-668

E-mail: info@messe-duesseldorf.de · http://www.rehacare.de

In the United States:

Messe Düsseldorf North America

150 North Michigan Avenue, **Suite 2920** Chicago, IL 60601

Tel:+1 (312) 781 51 80 · Fax:+1 (312) 781 51 88

E-Mail: info@mdna.com

Website: http://www.mdna.com

Altenpflege+ProPflege – Trade fair with convention for seniors care + therapy and professional patient care

Organizer:

NürnbergMesse GmbH

Messezentrum · 90471 Nürnberg

Tel: +49-911-8606-0 · Fax: +49-911-8606-8228

http://www.nuernbergmesse.de E-mail: info@nuernbergmesse.de

Project team:

Tel: +49-911-8606-8642 · Fax: +49-911-8606-8259

E-mail: propflege@nuernbergmesse.de · http://www.propflege.info

In the United States:

Concord Expo Group Kathy Donnelly P.O. Box 218 USA-Cocolalla, ID 83813

Tel: +1 (0) 2 08.265 17 14 · Fax: + 1(0) 2 08.265 17 13

E-mail: conexpogrp@earthlink.net http://www.concordexpogroup.com

ORTHOPAEDE + REHA TECHNIK - International trade fair and world convention for orthopedis and rehabilitation

Organizer:

Bundesinnungsverband für Orthopädie-Technik

Reinoldistr. 7-9 · 44135 Dortmund

Tel: +49-231-557050-0 · Fax: +49-231-557050-40

http://www.ot-forum.de E-mail: info@ot-forum.de

Project team:

Tel: +49 231 557050-0 · Fax: +49 231 557050-40

E-mail: ort2004@ot-forum.de

In the United States:

Frau / Ms Lisa Sormann

Tel.: 001-212-974 8841 · Fax: 001-212-974 8838

E-Mail: Leipzig-Tradeshows@gaccny.com · http://www.gaccny.com

EXPOPHARM - International Pharmaceutical Trade fair

Organizer:

Werbe- und Vertriebsges. Deutscher Apotheker mbH

Carl-Mannich-Straße 26 · 65760 Eschborn

Tel: +49-6196-928410 · Fax: +49-6196-928404

http://www.expopharm.de

Project team:

Expopharm Tel: +49-6196-928410 · Fax: +49-6196-928404

E-mail: expopharm@abda.de

U.S. Commercial Service Contact

Mr. Nils Roeher Commercial Specialist The Commercial Service - Düsseldorf

Tel: +49-211-737 767 20 Fax: +49-211-737 767 67

Email: Nils.Roeher@mail.doc.gov

The U.S. Commercial Service Germany can be contacted via e-mail at: dusseldorf.office.box@mail.doc.gov website: http://www.buyusa.gov/germany/en/.

You can locate your nearest U.S. Export Assistance Center, as well as Commercial Service offices overseas by visiting www.buyusa.gov.

To the best of our knowledge, the information contained in this report is accurate as of the date published. However, The Department of Commerce does not take responsibility for actions readers may take based on the information contained herein. Readers should always conduct their own due diligence before entering into business ventures or other commercial arrangements. The Department of Commerce can assist companies in these endeavors.